EP0341104B1

Substituted flavonoid compounds, their salts, their manufacture and medicines containing these materials.

Abstract

This record has no abstract on file.

EP0341104B1, drawing sheet 1
Sheet 1 of 210

Term

Term ended

Expired 6 April 2009, 17.5 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

10 claims: 1 independent, 9 dependent

  1. 1
    A compound of the formula (I):wherein:    X is N, O, Se, or S(O) n , wherein n is 0, 1 or 2;R₁ is phenyl;phenyl substituted by at least one member selected from the group consisting of halogens, C₁₋₁₂ alkyl, trifluoromethyl, hydroxyl, C₁₋₆ alkoxy, (̵C₁₋₆-alkylene)̵COOR₁₀, nitro, C₁₋₆(̵alkyl)̵carboylamino, benzoyl, C₁₋₆(̵alkyl)carboyl, CONR₁₀R₁₁, (where R₁₀ and R₁₁ are each independently H or C₁₋₆ alkyl), NR₁₀R₁₁, -N=N-NR₁₀R₁₁, phenyl, -O(̵C₁₋₆ alkylene)̵NR₁₀R₁₁, thiazolyl, and thiazolyl substituted by C₁₋₆ alkyl or amino;or R₁ is pyridyl;pyridyl substituted by at least one member selected from the group consisting of C₁₋₆ alkyls and halogens;trifluoromethyl;benzoyl or benzyl;R₂ is H;phenyl;OH;C₁₋₃ alkyl;or C₁₋₃ alkoxy;or    R₁ and R₂ together form a naphthalene ring fused to to the flavonoid nucleus;R₃ is H;OH;or halogen;R₄ is H;R₅ is H or C₁₋₃ alkyl;R₆ is H;OH;or -O-CO(̵C₁₋₆ alkyl);or R₅ and R₆ together are a group =CR₁₀R₁₁, or a group =NOH, or a group =O or a group =CHR₁₂ (where R₁₂ is phenyl, pyridyl, phenyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C₁₋₃ alkyls or pyrridyl substituted by at least one member selected from the group consisting of halogen atoms, trifluoromethyl and C₁₋₃ alkyls);R₇ is H;COOR₁₀;-P(O)(OR₁₀R₁₁)₂;NR₁₃R₁₄ (where R₁₃ and R₁₄ are independently H;phenyl;phenyl substituted by a halogen atom or a C₁₋₃ alkyl group or a group -COOR₁₀, -CO-O-CH(CH₃)-COOR₁₀, morpholinyl, -C(CH₂OH)₂(CH₃), imidazolinyl, (̵C₁₋₆ alkylene)̵OH, (̵C₁₋₆ alkylene)̵COOR₁₀, or C₁₋₃ alkoxy, or wherein R₁₃ and R₁₄ together with the nitrogen atom to which they are both bound from an imidazole or a N(̵C₁₋₃ alkyl)̵piperazinyl);or    R₇ is -CO(̵C₁₋₆ alkyl);-S-(C₁₋₆ alkyl);-SH;-S-CO(̵C₁₋₃ alkyl);(with 0 < m ≦ 6);-O(̵C₁₋₆ alkylene)̵NR₁₀R₁₁;-NR₁₀NR₁₀R₁₁;C₁₋₆ alkyl;thiazolyl;thiazolyl substituted by at least one member selected from the group consisting of -NH₂, C₁₋₃ alkyl, phenyl, and COOR₁₀;-NR-CO(̵C₁₋₃-alkyl);or (̵C₁₋₃-alkylene)̵CH(NH₂(COOH);or    -CR₅R₆R₇ is a group of the formula    wherein Q is at least one member selected from the group consisting of H;COOR₁₀;phenyl;-O(̵C₁₋₃-alkylene)̵COOR₁₀;C₁₋₃ alkyl;-O-CS-NR₁₀R₁₁;-O(̵C₁₋₃-alkylene)̵NR₁₀R₁₁;OH;C₁₋₃ alkoxy;and NR₁₀R₁₁;or    wherein any two of R₃, R₄, R₅, R₆ and R₇ together form a benzene ring;or a benzene ring substituted by (̵C₁₋₃-alkylene)̵COOR₁₀;(̵C₁₋₃-alkyl)̵OH, COOR₁₀, or (̵C₁₋₃-alkylene)̵O-CO(̵C₁₋₃-alkyl);or a naphthalene system;or a naphthalene system substituted by (̵C₁₋₃-alkylene)̵COOR₁₀, (̵C₁₋₃-alky)̵OH, COOR₁₀, or (̵C₁₋₃-alkylene)̵O-CO(̵C₁₋₃-alkyl);and    physiologically acceptable salts thereof, with the proviso that    when R₂, R₃, R₄, R₅ and R₆ are all H and R₇ is COOR₁₀, R₁ is other than phenyl, 2-thenyl, 3-methoxy phenyl, 3,4-dimethoxy phenyl, 2-furyl, para-tolyl, 2-naphthyl, 4-methoxy phenyl, cyclohexyl, benzyl, or methyl.
  2. 3
    The compound of Claim 1, wherein R₁ is phenyl substituted by one halogen atom.
  3. 4
    The compound of Claim 1, wherein R₇ is -COOR₁₀, -P(o)(OR₁₀R₁₁), -CH₂CH₂COOR₁₀ or -CONR₁₀R₁₁.
  4. 5
    The compound of Claim 1, wherein said compound has the formula (IV):wherein:    AR₂₆ is phenyl, substituted phenyl or biphenyl;R₂ is hydrogen, hydroxyl, or C₁₋₃ alkoxy;R₂₂ is hydrogen or hydroxyl;R₂₃ is hydrogen or fluoro;R₂₄ is hydrogen or hydroxy;R₂₅ is hydrogen, 2-methylpyridyl, benzylidene, 4-methylenepyridyl or methylene;or    R₂₂ and R₂₃ together form a benzene ring fused to the flavonoid nucleus;or    R₂₃ and R₂₄ together form a benzene ring fused to the flavonoid nucleus;or    R₂₅ and R₂₄ together form a benzene ring fused to the flavonoid nucleus.
  5. 7
    A pharmaceutical composition comprising a compound of Claim 2, 3 or 4 and a pharmaceutically acceptable carrier.
  6. 8
    A pharmaceutical composition comprising a compound of Claim 5, and a pharmaceutically acceptable carrier.
  7. 9
    The compound of Claim 1, wherein said compound is
  8. 10
    The compound of Claim 1, wherein said compound is